Reduction – Smoke Master

After a Decade-Long ‘War on Vaping,’ Is the FDA Finally Embracing Tobacco Harm Reduction?

admin — Wed, 16 Sep 2026 16:14:51 +0000

After almost a decade of conflict between the U.S. Food and Drug Administration (FDA) and the vaping industry, there are signs that America’s approach to tobacco harm reduction could be entering a different phase.

Economist Dr Raymond March, Director of FDAReview.org and a Research Fellow at the Independent Institute, recently delivered a highly critical assessment of the agency’s record on RegWatch. He described FDA policy as a sustained “war on vaping” that has restricted products, burdened independent manufacturers and contributed to public confusion about the relative risks of vaping and smoking.

Whether that characterisation is accepted or not, the FDA’s treatment of vaping has undoubtedly been contentious. But the appointment of Bret Koplow, Ph.D., J.D., as permanent director of the Center for Tobacco Products (CTP) could indicate a more pragmatic direction—one that combines strict youth protection with greater recognition of lower-risk alternatives for adults who smoke.

How did the FDA-Vaping conflict come along?

The roots of the saga stretch back to the FDA’s 2016 deeming rule, which extended the agency’s tobacco authority to e-cigarettes and required manufacturers to obtain marketing authorisation. The subsequent Premarket Tobacco Product Application (PMTA) process became particularly controversial. Millions of product applications ultimately received marketing denial orders, while others were left pending. Manufacturers suffered high costs, changing requirements, and uncertainty about the evidence needed to gain authorisation.

Political alarm over youth vaping, the rise and subsequent regulatory problems of Juul, and FDA prevention initiatives such as “The Real Cost” campaign further transformed vaping from a relatively small regulatory issue into a major public-health and political battle. March argues that the result disproportionately damaged independent vaping companies while favouring large corporations better equipped to absorb enormous regulatory costs.

He also criticises the FDA for failing to adequately address widespread misunderstanding of relative risk. That concern has significance beyond the vaping industry because smokers’ decisions depend partly on whether they understand that the primary danger from cigarettes comes from inhaling the products of combustion.

Independent evidence increasingly supports vaping’s role in helping smokers leave cigarettes behind. The latest Cochrane living review found high-certainty evidence that nicotine vapes produce higher smoking-cessation rates than nicotine replacement therapy, reinforcing the argument that access to regulated vaping products can have a legitimate public-health role.

Bret Koplow may be the change the FDA needed

The FDA’s newest leadership decision therefore deserves attention. Koplow, who had already been acting CTP director, has now been given the position permanently. According to the Department of Health and Human Services (HHS), his responsibilities will include promoting innovation and access to less harmful alternatives for adults who smoke while protecting young people from nicotine and tobacco use.

That language reflects the fundamental balance tobacco harm reduction advocates have long requested: differentiate products by risk while preventing youth uptake. More importantly, Koplow’s actions while serving as acting director suggest this may be more than rhetoric. In June, the FDA authorised 20 ZYN nicotine pouch products to carry a modified-risk claim explaining that switching completely from cigarettes to ZYN reduces the risk of several serious smoking-related diseases. Koplow said accurate information about relative harms could help adult smokers make informed decisions.

The agency had previously authorised another six nicotine pouch products through an accelerated review pilot, with Koplow explicitly describing them as lower-risk alternatives that expand options for adults who smoke.

Is the door to innovation finally being opened?

Perhaps the most significant shift has occurred with vaping itself. In May 2026, the FDA authorised fruit-flavoured e-cigarettes for adult smokers for the first time. Rather than treating flavour and youth protection as necessarily incompatible, Koplow highlighted technology designed to prevent underage access as potentially transformative. The decision suggests a regulatory model in which innovation could address competing objectives: preserving products that may appeal to adult smokers while using technological safeguards to restrict youth access.

Koplow has also pushed for changes to the PMTA system. In May, he argued that more efficient reviews could allow products meeting the required public-health standard to reach adults who could use them to reduce their risk of premature death and chronic disease. None of this means enforcement is disappearing. Koplow has rightly taken a strong position against unauthorised nicotine products resembling candy or everyday consumer items, particularly where their design could attract children or create accidental-ingestion risks.

The emerging philosophy therefore looks less like deregulation and more like risk-proportionate regulation: facilitate scientifically supported alternatives for adult smokers while acting aggressively against products and marketing practices that threaten youth.

Moving from senseless war to sensible regulations

March’s criticism represents one side of a long-running argument over whether FDA regulation has protected public health or inadvertently protected cigarettes from competition. What happens next may prove more important than settling that historical debate.

The FDA regulates a market in which cigarettes—the most dangerous widely used nicotine product—coexist with non-combustible alternatives capable of delivering nicotine without burning tobacco. A coherent regulatory system should recognise those differences while ensuring that products intended for adult smokers do not create unnecessary risks for children.

Koplow’s appointment does not guarantee a revolution in FDA tobacco policy. But his record, combined with HHS’s explicit commitment to improving access to less harmful alternatives, provides reasons for cautious optimism. After years in which the FDA was seen as waging a “war on vaping,” the more consequential question may now be whether the agency is finally prepared to make tobacco harm reduction a central part of its strategy for ending smoking-related disease.

Clickbait Obsession: Makary’s FDA Exit Revealed Media’s Preference for Political Theater Over Science

Source link

As Vaping Expands, Smoking Keeps Falling: New Zealand and U.S. Data Strengthen the Case for Tobacco Harm Reduction

admin — Wed, 02 Sep 2026 15:37:08 +0000

…the volume of smoked tobacco entering the legal retail market fell 22% in a single year and 58% compared with 2015. While New Zealand Health Survey data put daily adult smoking at 6.8% in 2024/25, down from 16.4% in 2011/12.

New Zealand’s latest tobacco figures are adding weight to a pattern increasingly difficult for policymakers to overlook: countries where smokers have meaningful access to vaping are continuing to record historically low levels of cigarette use. The country’s 2025 tobacco returns show the volume of smoked tobacco entering the legal retail market fell 22% in a single year and 58% compared with 2015. While New Zealand Health Survey data put daily adult smoking at 6.8% in 2024/25, down from 16.4% in 2011/12. The estimated number of daily smokers has nearly halved over that period.

The trend has coincided with the emergence of vaping as a mainstream alternative. Daily vaping increased from just 0.9% in 2015/16 to 11.7% in 2024/25. New Zealand’s Ministry of Health cautions that these parallel trends cannot establish that vaping caused the decline in smoking. Nevertheless, the substitution pattern is notable: as vaping became increasingly established, smoking moved sharply in the opposite direction.

For the Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA), New Zealand provides a particularly relevant case study for neighbouring governments that continue to prohibit or heavily restrict lower-risk nicotine products. Executive Coordinator Nancy Loucas argues that the results challenge predictions that regulated vaping access would derail progress against cigarettes.

Smoking decreases as vaping increases (worldwide)

New Zealand is hardly alone in demonstrating that widespread availability of novel nicotine products does not inevitably lead to higher smoking prevalence. The latest U.S. National Youth Tobacco Survey provides another striking example. In 2025, just 1.4% of middle and high school students reported currently smoking cigarettes. Meanwhile, vaping was 5.2%, while nicotine pouch use remained comparatively low at 1.7%. Overall youth use of cigarettes, vaping products and tobacco products declined between 2022 and 2025.

These figures contrast dramatically with the U.S. youth smoking epidemic of previous decades. They also complicate the argument that introducing alternative nicotine products must inevitably renormalise cigarette smoking. Naturally, population trends alone cannot prove vaping caused declining smoking rates; taxation, smoke-free laws, changing social attitudes, prevention campaigns and other factors all contribute.

Yet the much-feared and discussed reversal in cigarette-smoking declines following the arrival of e-cigarettes has not materialised. Instead, cigarettes have become increasingly uncommon among young Americans while vaping has also retreated substantially from its 2019 peak.

That distinction is really important. While it’s crucial to prevent young people from starting nicotine, tackling vaping and eliminating smoking are not the same public health goals. Cigarettes are especially dangerous since the combustion process creates a toxic mix that leads to most tobacco-related diseases.

Evidence for vaping as a smoking cessation tool keeps strengthening

Beyond population trends, randomised controlled trials now show much more convincing evidence that vaping can actually help adult smokers quit. The latest update of the Cochrane living systematic review, which includes data up to January 2026, found with high certainty that nicotine e-cigarettes lead to higher smoking cessation rates compared to conventional nicotine replacement therapy (NRT).

In seven trials with 2,544 participants, nicotine vaping increased quit rates by 59% compared to NRT. To put it simply, about eight to ten out of every 100 people using nicotine e-cigarettes managed to quit for at least six months, while roughly six out of 100 who used patches, gum, or other NRT were successful.

That places vaping firmly within the evidence-based smoking cessation toolkit rather than merely making it an alternative consumer product.

Other smoke-free nicotine technologies may broaden that toolkit further. Nicotine pouches eliminate both tobacco combustion and inhalation, potentially providing another option for smokers who do not want to vape. Their evidence base specifically for smoking cessation remains less developed than that for e-cigarettes, so claims of cessation effectiveness should remain proportionate to the available research. Their toxicological profile, however, differs fundamentally from combustible cigarettes because they do not generate smoke.

A model to follow

New Zealand has increasingly attempted to combine adult access with measures intended to prevent youth uptake. Its government explicitly recognises less harmful alternatives such as vaping as practical tools for smokers trying to quit. CAPHRA argues that this approach deserves particular consideration across Asia, where millions continue to smoke while several governments favour prohibition or severe restrictions on vaping.

Clarisse Virgino, CAPHRA’s Philippines representative, maintains that the central policy mistake is treating every nicotine product as though it carries the same level of risk. A risk-proportionate system would instead distinguish combustible cigarettes from non-combustible alternatives while enforcing age restrictions and product standards.

There are important qualifications. New Zealand authorities acknowledge that illicit cigarettes could account for part of the accelerated reduction in legal tobacco sales, while persistent smoking inequalities remain, particularly among Māori and more deprived communities. These challenges reinforce the need for targeted cessation support rather than complacency.

The undeniable case for tobacco harm reduction

The broader evidence nevertheless presents policymakers with a clearer choice. Countries can attempt to eliminate nicotine use altogether, potentially restricting alternatives alongside the cigarettes responsible for the overwhelming burden of disease. Or they can pursue the more pragmatic objective of eliminating smoking by encouraging consumers who cannot or will not quit nicotine to move down the risk continuum.

New Zealand’s experience may not prove that vaping alone caused its remarkable decline in smoking. However, it does show that widespread access to vaping goes hand in hand with decreased smoking rates.

Combined with historically low U.S. youth smoking and high-certainty clinical evidence that nicotine vapes outperform NRT for cessation, the case for tobacco harm reduction is becoming increasingly difficult to dismiss. The priority should remain the product causing the greatest harm: combustible cigarettes.

Punished for Success? New Zealand’s “Dirty Ashtray” Reveals The FCTC’s Embedded Bias

Source link

80,000 Responses Later, Will the EU Listen to the Evidence on Tobacco Harm Reduction?

admin — Thu, 27 Aug 2026 15:30:05 +0000

The European Union is entering a potentially decisive period for tobacco harm reduction. With its latest tobacco consultation now closed, Brussels must decide whether future regulation will recognise the very different risks posed by cigarettes, vapes, heated tobacco products and nicotine pouches—or increasingly treat them as variations of the same problem.

The European Commission launched its (second) public consultation on May 22 and closed it on August 14. Together with an earlier call for evidence, which attracted more than 80,000 responses, the exercise will inform revisions of the Tobacco Products Directive and Tobacco Advertising Directive expected before the end of 2026. The Commission says existing rules have helped reduce smoking and tobacco-related mortality, but argues that rapid growth in newer nicotine products, particularly among young people, requires the framework to be modernised.

Was the consultation truly neutral?

Yet even before the responses have been fully analysed, controversy has shifted from what Brussels might regulate to how it has sought public input. University of Catania professor Riccardo Polosa told Eunews that the questionnaire’s design raised concerns about both transparency and the quality of the process. He described it as unnecessarily complicated and argued that some questions appeared to channel respondents towards predetermined categories and policy choices.

His concern is particularly relevant to tobacco harm reduction because combining fundamentally different nicotine products within broad regulatory questions can obscure differences in relative risk. Polosa argues that reducing smoking-related disease and mortality should remain the central objective and that future EU legislation should clearly distinguish combustible cigarettes from non-combustible alternatives.

This is more than a technical debate over survey design. The consultation will feed into legislation that could affect hundreds of millions of European consumers, while the existing Tobacco Products Directive (TPD) already regulates cigarettes, smokeless tobacco and e-cigarettes, among other categories. The question is whether the next framework will become more risk-proportionate—or move towards increasingly similar treatment of all nicotine products.

Protecting youth without protecting cigarettes

Brussels may have moderately legitimate reasons to address youth uptake. The Commission has specifically identified newer tobacco and nicotine products and their popularity among younger consumers as an emerging public-health challenge. Health Commissioner Olivér Várhelyi, who is known to be very anti-tobacco harm reduction strategies, has specifically framed the review around keeping regulation abreast of a changing market and protecting young people from new forms of dependence.

However, preventing youth nicotine use and encouraging adults to stop smoking do not have to be competing objectives. Age restrictions, responsible retailing, product standards and appropriately designed marketing rules can protect minors without removing potentially valuable alternatives from adults who smoke. The danger comes when youth protection becomes justification for eliminating distinctions between combustible and smoke-free products.

Risk perceptions are already moving in the wrong direction. ASH data for Great Britain found that in 2025, 56% of adults who had heard of vaping believed it was equally or more harmful than cigarettes, while only 28% correctly identified vaping as less harmful. As 53% believed vaping was equally or outright more harmful. For smokers deciding whether to switch, such misconceptions are hardly inconsequential.

The excellent model that Europe refuses to acknowledge

Norwegian tobacco researcher Karl E. Lund believes policymakers should look more closely at Scandinavia. Rather than focusing exclusively on eliminating nicotine consumption, Lund argues that regulation should help people who cannot or do not wish to stop using nicotine move away from smoking. Sweden is particularly important because cigarettes have increasingly been displaced by non-combustible alternatives such as snus and nicotine pouches.

Like many of his peers, Lund describes the Scandinavian approach as one of risk-proportionate regulation: products are not automatically treated identically simply because they contain nicotine. He argues that creating barriers to lower-risk alternatives while cigarettes remain readily available is difficult to reconcile with reducing smoking-related harm.

That argument becomes increasingly relevant when considering the estimated 90–100 million Europeans who still smoke despite decades of taxation, advertising restrictions, health warnings and smoke-free policies. Traditional tobacco control has achieved substantial progress. The issue is whether the remaining smoking population will respond to ever-tighter versions of the same policies—or whether substitution should become a larger part of Europe’s strategy.

Harsh restrictions support the illicit market

The growing belief that vaping is as dangerous as smoking demonstrates what can happen when public-health messages emphasise uncertainty without adequately explaining the magnitude of risk.

Retailers have raised another concern: poorly calibrated regulation may shift sales rather than eliminate demand. The European Confederation of Tobacco Retailers has warned that disproportionate restrictions could disadvantage compliant businesses while benefiting illicit sellers. Lund has raised similar concerns, arguing that regulators need to consider the real-world consequences of making legal alternatives less attractive or accessible.

Perhaps the most overlooked issue in the consultation is how Europe communicates relative risk. The growing belief that vaping is as dangerous as smoking demonstrates what can happen when public-health messages emphasise uncertainty without adequately explaining the magnitude of risk. Even youth data challenge the assumption that exaggerated perceptions necessarily discourage experimentation: in 2024, 58% of British 11–17-year-olds who knew about vaping believed it was as harmful or more harmful than smoking, yet ASH noted that such beliefs did not appear to prevent young people from trying vapes.

Accurate communication therefore matters for both credibility and informed decision-making.

Non-combustible nicotine products should not be promoted to non-users. But neither should their risks be communicated in ways that leave smokers believing there is little health advantage in abandoning cigarettes.

What will Brussels do with the responses this time round?

Stricter tobacco-control groups are pushing Brussels in the opposite direction, calling for tougher regulation of newer products, stronger restrictions on online promotion and greater freedom for Member States to impose additional measures. Agricultural representatives, meanwhile, have complained that the consultation did not adequately capture their sector’s concerns.

The Commission must now reconcile these competing perspectives and translate thousands of submissions into legislation. Its objective of (allegedly) creating a tobacco-free generation by 2040 provides an important clue to what should ultimately matter: reducing tobacco smoking and the disease it causes. The Commission itself describes the target as a tobacco-free generation, while confirming that the review will address the rapidly changing nicotine market.

Europe therefore faces a choice that extends well beyond flavours, advertising or packaging. It can increasingly regulate nicotine by its presence, or regulate products by their risks. For tobacco harm reduction advocates, the test of the consultation’s credibility will now be straightforward: whether Brussels genuinely listens to the evidence it asked Europeans to provide.

From Poland to Lithuania: Are Europe’s Nicotine Policies Reasonable or Going Too Far?

Source link

Vaping as a Harm Reduction Tool in the UK and the USA

admin — Thu, 13 Aug 2026 03:52:13 +0000

In the ongoing discourse surrounding vaping, it’s evident that the United Kingdom and the United States hold divergent views on its role and implications. While the UK appears more open to embracing vaping as a harm reduction strategy, the US often approaches it with caution and skepticism. Understanding these differing viewpoints requires a nuanced examination of various factors, including healthcare systems, cultural attitudes, and economic considerations. Here, we delve into why embracing vaping as a harm reduction tool is not only logical but also beneficial for public health, regardless of geographical location.

Harnessing Harm Reduction: A Pragmatic Approach

In the UK, the embrace of vaping as a harm reduction tool reflects a pragmatic understanding of public health. With the National Health Service (NHS) shouldering the burden of healthcare costs, there’s a vested interest in reducing the prevalence of smoking-related illnesses. Vaping presents a viable alternative to traditional cigarettes, with growing evidence suggesting it’s significantly less harmful. Public Health England’s assertion that vaping is 95% less harmful than smoking underscores the potential benefits of harm reduction strategies. By encouraging smokers to switch to vaping, the UK not only mitigates health risks but also reduces the strain on healthcare resources, ultimately benefiting society as a whole.

Empowering Individuals: A Liberty Perspective

In the US, where individual liberty is paramount, the reluctance towards vaping often stems from concerns about government overreach and personal freedom. However, framing vaping as a matter of individual choice overlooks its potential as a tool for harm reduction. By providing smokers with a less harmful alternative, vaping empowers individuals to make informed decisions about their health. Moreover, stringent regulations and prohibitive measures risk driving vaping underground, where safety standards are compromised, and consumers are exposed to greater risks. Embracing vaping within a harm reduction framework respects individual autonomy while prioritizing public health outcomes.

Economic Implications: A Fiscal Perspective

From an economic standpoint, the benefits of embracing vaping as a harm reduction tool are significant. In both the UK and the US, the reduction in smoking-related healthcare costs and productivity losses stands to yield substantial savings. Moreover, the burgeoning vaping industry presents opportunities for innovation, job creation, and economic growth. By fostering an environment that supports harm reduction strategies, policymakers can harness the economic potential of vaping while safeguarding public health.

Changing Cultural Narratives: A Shift in Perception

Cultural attitudes towards smoking and vaping are evolving, albeit at different paces. In the UK, where anti-smoking campaigns have gained traction, there’s greater acceptance of harm reduction approaches. Public Health England’s endorsement of vaping as a smoking cessation aid has helped destigmatize its use. Conversely, in the US, where the tobacco industry wields considerable influence, changing cultural narratives requires concerted efforts to counter misinformation and promote evidence-based discourse. By reframing vaping as a harm reduction tool rather than a gateway to smoking, attitudes can gradually shift towards a more nuanced understanding of its benefits.

Conclusion: Towards a Unified Approach

In conclusion, the disparity in viewpoints on vaping between the UK and the US underscores the need for a unified approach grounded in evidence-based policymaking and public health principles. Embracing vaping as a harm reduction tool offers a pragmatic solution to the challenges posed by smoking, benefiting individuals, societies, and economies alike. By transcending geopolitical boundaries and cultural divides, we can foster a global consensus that prioritizes public health while respecting individual freedoms. It’s time to bridge perspectives and embrace vaping as a force for positive change in the journey towards a smoke-free future.

Disclosure: The views expressed in this blog post are solely those of the author and do not necessarily reflect the opinions or policies of any organization, institution, or entity with which the author may be affiliated. These views are based on the author’s personal knowledge, research, and understanding of the topic at hand. Readers are encouraged to form their own opinions and conduct further research to make informed decisions.

Source link

Is the UK’s Latest Regulatory Shake-Up Leaning Towards Harm Reduction or Over-Regulation?

admin — Wed, 05 Aug 2026 03:43:20 +0000

Britain’s vaping sector is entering its most challenging period since e-cigarettes first emerged as a smoking alternative. New taxes, stricter product rules, tighter marketing restrictions and proposals targeting specialist vape retailers are converging at a time when around 5.5 million adults in Great Britain use vaping products, most of them former or current smokers.

For tobacco harm reduction advocates, the central question is no longer whether vaping should be regulated—it should—but whether new policies will continue encouraging smokers to switch away from cigarettes or inadvertently make combustible tobacco more competitive.

The debate took centre stage at the UK Vaping Industry Association’s (UKVIA) 2026 Forum in London, where regulators, parliamentarians, manufacturers, retailers and consumer representatives examined how Britain can tackle youth vaping and illicit products without undermining one of its most successful smoking reduction tools.

New duty could spell disaster

The most immediate change arrives on 1 October 2026 with the introduction of the UK’s Vaping Products Duty. Every 10ml bottle of e-liquid—whether it contains nicotine or not—will attract a flat-rate £2.20 excise duty, with VAT added on top. At the same time, manufacturers and importers must introduce digital tax stamps on qualifying products, enabling HM Revenue & Customs to monitor products throughout the supply chain.

Supporters argue that the measures will help reduce youth access while generating an estimated £525 million in revenue. However, many within the vaping sector fear unintended consequences.

Unlike the original proposal for nicotine-based tax bands, the flat-rate model taxes all liquids equally regardless of nicotine strength. Heavy users of lower-strength refillable liquids may therefore pay more than consumers using smaller quantities of higher-strength products.

The broader concern is whether higher prices narrow the financial advantage vaping currently holds over smoking. Multiple international economic studies have shown that cigarettes and vaping products can act as substitute goods. When vaping becomes substantially more expensive, some smokers postpone switching while some former smokers relapse. The latest Cochrane living review continues to find that nicotine e-cigarettes help more adults stop smoking than conventional nicotine replacement therapy, suggesting that maintaining affordability remains an important component of tobacco harm reduction.

Flavours seem next on the list

Alongside taxation, flavour regulation has become one of the most contested issues in UK tobacco policy. The government has launched a consultation proposing restrictions on packaging, branding and colours, simplified flavour descriptions and keeping vaping products out of sight in shops. Yet while protecting children from nicotine use remains a legitimate public health objective, the evidence increasingly suggests policymakers should distinguish between youth-oriented marketing and flavours themselves.

Research presented by UKVIA indicates that non-tobacco flavours remain important for adult smokers trying to distance themselves from cigarettes. Similar findings have emerged from local authority stop-smoking services, where fruit flavours are widely supplied to smokers attempting to quit. This distinction matters.

A flavour description such as “strawberry” simply informs consumers what a product tastes like. Cartoon imagery, confectionery branding or designs clearly intended to appeal to children represent a separate issue and can be regulated independently. Treating every non-tobacco flavour as inherently problematic risks making smoke-free alternatives less appealing to adults, without necessarily reducing youth experimentation.

Specialist vape shops? Totally underrated

The regulatory challenges extend beyond products themselves.

Recent government statements suggesting that relief for businesses “that do not make a positive contribution to local communities, such as vape shops” should be reviewed have generated strong criticism from harm reduction advocates.

The implication that specialist vape retailers contribute little to society sits uneasily alongside evidence that millions of former smokers rely on these businesses for advice, product selection and ongoing support.

Unlike convenience stores, specialist vape shops employ trained staff capable of helping smokers choose appropriate devices, nicotine strengths and refillable systems. Many consumers credit these retailers with helping them remain smoke-free after multiple unsuccessful quit attempts. While smoking still kills approximately half of long-term smokers, the contribution made by specialist retailers cannot easily be dismissed.

Licensing goes hand in hand with enforcement

Rather than targeting legitimate businesses, many industry representatives favour a comprehensive licensing system.

UKVIA and several retailers have proposed licensing manufacturers, distributors and retailers, with licence fees funding Trading Standards enforcement against illegal sellers.

The Tobacco and Vapes Act already provides powers for retail licensing in much of the UK. If implemented effectively, licensing could improve market oversight while allowing regulators to suspend businesses repeatedly found selling to minors or distributing non-compliant products.

Digital tax stamps introduced alongside the Vaping Products Duty could reinforce this approach by making legal supply chains easier to trace. However, licensing will only succeed if enforcement focuses on illicit operators rather than imposing additional administrative burdens on compliant retailers.

Plain packaging risks sending the wrong message

Among the most controversial proposals are plans requiring vaping products to adopt plain packaging and drab colours similar to tobacco products. The intention is clear: reduce youth appeal.

The difficulty is that packaging performs several functions beyond marketing. For adult smokers considering switching, product appearance, brand recognition and clear information help distinguish legitimate products from counterfeit alternatives. Removing these features may unintentionally reinforce the misconception that vaping carries risks comparable to smoking.

Public perception is already moving in the wrong direction.

Recent surveys consistently show that many adults now believe vaping is as harmful as—or even more harmful than—combustible cigarettes despite repeated evidence reviews by Public Health England, the Office for Health Improvement and Disparities and the Royal College of Physicians concluding that vaping is substantially less harmful than smoking. If regulation further blurs this distinction, fewer smokers may see value in switching.

A defining moment for UK tobacco harm reduction

The UK has long been regarded as one of the world’s most progressive countries on tobacco harm reduction. Programmes such as Swap to Stop, widespread integration of vaping into Stop Smoking Services and evidence-based public health messaging have helped accelerate declines in smoking prevalence. The next phase of regulation will determine whether that progress continues.

Children should not vape. Illegal products should be removed from the market. Manufacturers should meet rigorous product standards, while retailers should verify age and comply with environmental obligations. Yet regulation must also preserve the accessibility, affordability and attractiveness of lower-risk alternatives for adults who would otherwise smoke.

Success should not be measured by declining vape sales alone.

Instead, policymakers should ask a more important question: are fewer people smoking as a result? If the answer remains yes, regulation will have achieved its purpose. If tighter restrictions simply make cigarettes relatively more attractive or push consumers into illicit markets, Britain risks weakening one of its most effective public health interventions.

The challenge facing policymakers is therefore not whether to regulate vaping, but how to do so without losing sight of the ultimate objective: replacing combustible cigarettes with substantially lower-risk alternatives and continuing to reduce the enormous burden of smoking-related disease.

Can the UK Britain Tackle Illicit Vapes Without Hurting Adult Smokers Trying to Quit?

Source link